Preventing and treating biologic-associated opportunistic infections

被引：38

作者：

Winthrop, Kevin L. ^{[1
]}

Chiller, Tom ^{[2
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] US Ctr Dis Control & Prevent, Atlanta, GA USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2009年 / 5卷 / 07期

关键词：

TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA ASSAY; TUBERCULOSIS INFECTION; LATENT TUBERCULOSIS; FACTOR ANTAGONISTS; RHEUMATOID-ARTHRITIS; FACTOR-ALPHA; DISEASES; COCCIDIOIDOMYCOSIS; RECOMMENDATIONS;

D O I：

10.1038/nrrheum.2009.105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. these pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. this article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.

引用

页码：405 / 410

页数：6

共 28 条

[1]

[Anonymous], 2003, MORBIDITY MORTALITY, V52

[2]

[Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221

[3]

Beglinger C, 2007, SWISS MED WKLY, V137, P621

[4] Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists [J].

Bergstrom, L ;

Yocum, DE ;

Ampel, NM ;

Villanueva, I ;

Lisse, J ;

Gluck, O ;

Tesser, J ;

Posever, J ;

Miller, M ;

Araujo, J ;

Kageyama, DM ;

Berry, M ;

Karl, L ;

Yung, CM .

ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1959-1966

[5] Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [J].

Carmona, L ;

Gómez-Reino, JJ ;

Rodríguez-Valverde, V ;

Montero, D ;

Pascual-Gómez, E ;

Mola, EM ;

Carreño, L ;

Figueroa, T .

ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1766-1772

[6]

Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P735

[7] Coccidioidomycosis [J].

Chiller, TM ;

Galgiani, JN ;

Stevens, DA .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (01) :41-+

[8]

de Leon DP, 2008, J RHEUMATOL, V35, P776

[9] Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy:: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment [J].

Denis, B. ;

Lefort, A. ;

Flipo, R. M. ;

Tubach, F. ;

Lemann, M. ;

Ravaud, P. ;

Salmon, D. ;

Mariette, X. ;

Lortholary, O. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (02) :183-186

[10] Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 [J].

Furst, D. E. ;

Keystone, E. C. ;

Kirkham, B. ;

Fleischmann, R. ;

Mease, P. ;

Breedveld, F. C. ;

Smolen, J. S. ;

Kalden, J. R. ;

Burmester, G. R. ;

Braun, J. ;

Emery, P. ;

Winthrop, K. ;

Bresnihan, B. ;

De Benedetti, F. ;

Doerner, T. ;

Gibofsky, A. ;

Schiff, M. H. ;

Sieper, J. ;

Singer, N. ;

Van Riel, P. L. C. M. ;

Weinblatt, M. E. ;

Weisman, M. H. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 :2-25

← 1 2 3 →